U.S. markets closed

Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7.6%

Zacks Equity Research

Outlook Therapeutics, Inc. OTLK was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of 51-66 cents per share in the past one-month time frame.

The company has seen no estimate revision in the past month, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Outlook Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Outlook Therapeutics, Inc. Price

Oncobiologics, Inc. Price

Outlook Therapeutics, Inc. price | Outlook Therapeutics, Inc. Quote

A better-ranked stock in the Medical – Biomedical and Genetics industry is Aravive, Inc. ARAV, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Oncobiologics, Inc. (OTLK) : Free Stock Analysis Report
 
ARAVIVE, INC (ARAV) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research